Northwest biotherapeutics announces agreement to acquire advent bioservices ltd.

Bethesda, md. , aug. 27, 2025 /prnewswire/ -- northwest biotherapeutics, inc. (otcqb:nwbo) (the "company" or "nwbio"), a biotechnology company developing dcvax® personalized immune therapies for solid tumor cancers, announced that it has entered into an agreement to acquire advent bioservices ltd.

ADN Ratings Summary

ADN Quant Ranking